Contribution of the Kinematic Theory in the Early Differential Diagnosis of the Parkinson's Disease
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
The working hypotheses are as follows: #1 The processing of performance signals by automated lognormal segmentation and the extraction of the parameters of interest will make it possible to distinguish groups of patients from healthy elderly subjects. #2 The three instrumental approaches will not have the same degree of reliability as a predictive biomarker of clinical diagnosis established by consensus.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Maximum Age: 75
Healthy Volunteers: t
View:
• Being diagnosed with Parkinsonism including idiopathic Parkinson's disease or a related syndrome;
• Have motor symptoms of Parkinsonism for 6 years or less;
• Be a healthy volunteer subject in good general health with no prior neurological history;
• Age between 50-75 years old;
• If applicable, be able to safely leave home in the morning without having taken antiparkinsonian medication for the past 12 hours.
Locations
Other Locations
Canada
CHUM/Université de Montréal
RECRUITING
Montreal
Contact Information
Primary
Pierre Blanchet, MD
pierre.j.blanchet@umontreal.ca
514-890-8123
Time Frame
Start Date: 2020-02-19
Estimated Completion Date: 2028-12
Participants
Target number of participants: 90
Treatments
Patients with Parkinson Disease (PD)
Participants will then have to perform three blocks of tests: the first focused on the scripted motor signature, a second on the voice signature, and a complementary block aimed at capturing the motor signature using gestures of greater amplitude.~All the tests were designed to allow the characterization of the motor signature according to different aspects of motor control, but also to reproduce the same concepts in the three fields (scripted signature, voice signature and large amplitude motor signature), while allowing an acquisition of an approximate total duration of 30 minutes.~For retinal photos, the subject's pupils will be dilated using eye drops (1% tropicamide and 2.5% phenylephrine) 15-20 minutes before taking the measurement. These drugs are considered the standard used by optometrists and ophthalmologists during pupil dilation.
Patients with atypical Parkinsonian Syndromes (PS)
Participants will then have to perform three blocks of tests: the first focused on the scripted motor signature, a second on the voice signature, and a complementary block aimed at capturing the motor signature using gestures of greater amplitude.~All the tests were designed to allow the characterization of the motor signature according to different aspects of motor control, but also to reproduce the same concepts in the three fields (scripted signature, voice signature and large amplitude motor signature), while allowing an acquisition of an approximate total duration of 30 minutes.~For retinal photos, the subject's pupils will be dilated using eye drops (1% tropicamide and 2.5% phenylephrine) 15-20 minutes before taking the measurement. These drugs are considered the standard used by optometrists and ophthalmologists during pupil dilation.
Healthy volunteers
Participants will then have to perform three blocks of tests: the first focused on the scripted motor signature, a second on the voice signature, and a complementary block aimed at capturing the motor signature using gestures of greater amplitude.~All the tests were designed to allow the characterization of the motor signature according to different aspects of motor control, but also to reproduce the same concepts in the three fields (scripted signature, voice signature and large amplitude motor signature), while allowing an acquisition of an approximate total duration of 30 minutes.~For retinal photos, the subject's pupils will be dilated using eye drops (1% tropicamide and 2.5% phenylephrine) 15-20 minutes before taking the measurement. These drugs are considered the standard used by optometrists and ophthalmologists during pupil dilation.
Related Therapeutic Areas
Sponsors
Leads: Centre hospitalier de l'Université de Montréal (CHUM)
Collaborators: Optina Diagnostics Inc.